In an open multi-centre study, 51 patients with mild to moderate hypertension were treated with either a single dose of 40 mg penbutolol per day for 8 weeks or changed over at 4 weeks due to inadequate response with penbutolol alone to a single dose (1 tablet) of a fixed combination of 40 mg penbutolol and 20 mg furosemide per day for a further 4 weeks. Thirty-six (70%) of the patients showed an adequate reduction in diastolic blood pressure to 95 mmHg or less on penbutolol alone. Of the 15 patients who did not show the desired response to penbutolol alone, 13 (86.7%) showed a satisfactory reduction in blood pressure after 4 weeks on the combination product; 2 of these patients had received 1 tablet twice daily from Week 6 of treatment. Two other patients received 1 tablet of the combination twice daily from Week 8 onwards for 2 weeks. Only 1 of them did not respond to this therapy. Blood pressure reduction and weight loss were significantly greater on the combination product than on penbutolol alone. No clinically significant changes were noted in serum potassium, glucose, creatinine or uric acid levels, and mild gastric side-effects at the beginning of treatment were reported in only 3 patients, 1 of whom was also receiving indomethacin.

Download full-text PDF

Source

Publication Analysis

Top Keywords

blood pressure
12
fixed combination
8
combination penbutolol
8
penbutolol furosemide
8
single dose
8
day weeks
8
response penbutolol
8
combination product
8
patients received
8
received tablet
8

Similar Publications

Background: Hemoglobin (Hb) Hekinan is a prevalent α-globin variant frequently missed in thalassemia screening centers using high-performance liquid chromatography (HPLC) or capillary electrophoresis. This study aims to investigate the hematological and molecular characteristics of Hb Hekinan in a large cohort.

Methods: Hb variants were identified using isoelectric focusing (IEF) and HPLC.

View Article and Find Full Text PDF

Background: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or the CGRP-receptor have revolutionized the prevention of migraine. Despite their effectiveness, worries have surfaced regarding potential unwanted cardiovascular effects linked to the vasodilation function of CGRP, suggesting a potential influence on blood pressure (BP).

Methods: Studies were systematically retrieved from PubMed, Cochrane Database of Systematic Reviews, Web of Science, MEDLINE and EMBASE up to 1 May 2024.

View Article and Find Full Text PDF

Background: Atrial fibrillation (AF) and heart failure (HF) often coexist and impact morbidity and mortality. There is limited knowledge on the association of AF subtypes with HF according to sex.

Objectives: The purpose of this study was to explore sex-specific associations between AF subtypes and subsequent HF, identifying HF risk factors in participants with AF, and exploring the combined impact on mortality.

View Article and Find Full Text PDF

Background: Portopulmonary hypertension (PoPH) occurs in patients with advanced liver disease and can be a contraindication to liver transplant (LT). Improvement of hemodynamic parameters with pulmonary arterial hypertension (PAH) therapies (including endothelin receptor antagonists [ERAs]) may help some patients to become eligible for LT.

Methods: We conducted a retrospective secondary data analysis to describe the clinical course and management of PoPH in patients on a US registry LT waitlist and outcomes in patients receiving an ERA.

View Article and Find Full Text PDF

Background: Normothermic machine perfusion (NMP) provides a platform for kidney quality assessment. Donation after circulatory death (DCD) donor kidneys are associated with great ischemic injury and high intrarenal resistance (IRR). This experimental study aims to investigate the impact of different perfusion pressures on marginal kidney function and injury during NMP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!